THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial

Disclosure: M. Gadelha: Advisory Board Member; Self; Novo Nordisk, Recordati, Crinetics Pharmaceuticals. Speaker; Self; Recordati, Novo Nordisk, Ipsen, Crinetics Pharmaceuticals. M.D. Bronstein: None. E. Grineva: Advisory Board Member; Self; Ipsen, Merck, Pfizer, Inc. Speaker; Self; Recordati, Ipsen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Mônica, Bronstein, Marcello Delano, Grineva, Elena, Kapoor, Nitin, De Block, Christophe, Escalante Pulido, Jesus Miguel, Rollin, Guilherme, Baggenstoss, Rejane, Piacentini, Andrea, Pedroncelli, Alberto M, Gallardo, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554173/
http://dx.doi.org/10.1210/jendso/bvad114.1146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554173/
http://dx.doi.org/10.1210/jendso/bvad114.1146

Ejemplares similares